← 返回

皮肤黑色素瘤中 NK 细胞相关基因的综合表征鉴定出预测预后、免疫治疗和化疗疗效的新型预后标签

英文原题:Comprehensive characterization of NK cell-related genes in cutaneous melanoma identified a novel prognostic signature for predicting the prognosis, immunotherapy, and chemotherapy efficacy.

查看英文原题

Comprehensive characterization of NK cell-related genes in cutaneous melanoma identified a novel prognostic signature for predicting the prognosis, immunotherapy, and chemotherapy efficacy.

PubMed 2025/07/01(内容时间) Discov Oncol Q3 · IF 2.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本研究建立了一种新的 NKIGs 特征,具有预测 CM 患者预后和指导个性化治疗方案的显著潜力。

研究思路结论见上方概要

自然杀伤(NK)细胞作为固有免疫系统的关键效应细胞,在肿瘤预后和免疫治疗中发挥重要作用。本研究旨在基于NK细胞相关免疫基因(NKIGs)为皮肤黑色素瘤(CM)患者构建预测模型,并评估其在预测预后和指导个体化治疗中的效用。

从癌症基因组图谱(TCGA)数据库获取CM患者的RNA测序数据和临床信息,同时从基因型-组织表达(GTEx)数据库获取正常皮肤样本的表达谱。结合免疫基因对CM的单细胞转录组进行分析,以识别NKIGs。随后利用单因素Cox回归和LASSO-Cox分析,使用这些基因构建预后模型。通过多种统计方法评估模型的准确性和有效性。探索了NKIGs特征所定义组别的免疫学特征,以及免疫治疗和化疗的有效性。此外,通过体外RT-qPCR实验验证了NKIGs的表达水平。

根据NKIGs特征确定的低风险组患者的总生存期(OS)显著优于高风险组。低风险组还显示出更高的免疫细胞浸润,尤其是CD8 T细胞和活化的CD4记忆T细胞。

展开英文摘要原文

Natural killer (NK) cells, as key effectors of the innate immune system, play a crucial role in cancer prognosis and immunotherapy. This study aimed to develop a predictive model based on NK cell-associated immune genes (NKIGs) for patients with cutaneous melanoma (CM) and to assess its utility in predicting prognosis and guiding personalized treatment.

RNA-sequencing data and clinical information of CM patients were retrieved from The Cancer Genome Atlas (TCGA) database, while expression profiles from normal skin specimens were obtained from the Genotype-Tissue Expression (GTEx) database. Single-cell transcriptomes from CM were analyzed in conjunction with immune genes to identify NKIGs. These genes were then utilized to construct a prognostic model using univariate Cox regression and LASSO-Cox analysis. The model's accuracy and efficacy were evaluated through various statistical methods. Immunological characteristics, as well as the effectiveness of immunotherapy and chemotherapy in groups defined by the NKIGs signature, were explored. Additionally, the expression levels of NKIGs were validated via RT-qPCR in vitro experiments.

The overall survival (OS) of patients in the low-risk group, as determined by the NKIGs signature, was significantly better than the high-risk group. The low-risk group also showed higher immune cell infiltration, particularly of CD8 T cells and activated CD4 memory T cells.

This study has established a novel NKIGs signature with significant potential for predicting prognosis and guiding personalized therapeutic approaches in CM patients.

论文信息

作者
Ma H、Liu J、Jin H、Zhang M、Liang Q、Guo Z
第一作者单位
Department of Gynecology and Obstetrics, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Nanjing Medical University, Wuxi People's Hospital, Wuxi, 214000, Jiangsu, People's Republic of China.China
通讯作者单位
Department of Otolaryngology-Head and Neck Surgery, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, 201700, Shanghai, People's Republic of China. gzqhblove@126.com.China
期刊
Discover oncology2025 Jul 1
原文标识
PubMed 40591154 · DOI 10.1007/s12672-025-03074-1